证券研究报告 非银金融 | 保险Ⅱ 港股|首次覆盖报告 hyzqdatemark 2025 年 12 月 18 日 证券分析师 陆韵婷 SAC：S1350525050002 luyunting@huayuanstock.com 沈晨 SAC：S1350525090002 shenchen@huayuanstock.com 市场表现： | 基本数据 | 2025 | 年 | 12 | 月 17 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 3.21 | | | 一年内最高/最低（港 | | | | 7.36/0.87 | | | 元） | | | | | | | 总市值（百万港元） | | | | 13,030.33 | | | 流通市值（百万港元） | | | | 13,030.33 | | | 资产负债率（%） | | | | 84.60 | | | 资料来源：聚源数据 | | | | | | 云锋金融(00376.HK) 投资评级： 买入（首次） ——新业务价值高增，投资管理能力独特 投资要点： 联系人 扎根香港寿险市场，兼具强 ...

Investment Rating - The report suggests a cautious subscription for the company’s IPO [2]. Core Insights - The company is a leading provider of real-time data infrastructure and analytical solutions in China, primarily serving the asset management industry with a market share of 11.6% as of 2024 [2][3]. - The real-time data infrastructure market in China is projected to grow from RMB 18.7 billion in 2024 to RMB 50.5 billion by 2029, with a compound annual growth rate (CAGR) of 22.0% from 2024 to 2029 [3]. - The company’s revenue growth is expected to decline significantly, with a forecasted drop from 84.3% in 2023 to a negative 30.0% in the first half of 2025, alongside an increase in net loss margin from 12.0% in 2023 to 54.6% in the first half of 2025 [3]. Summary by Sections IPO Details - The IPO price range is set between HKD 48.00 and HKD 55.00, with a total fundraising amount of approximately HKD 1.04 billion [1]. - The total number of shares available for subscription is 2.25 million, with 90% allocated for international placement and 10% for public offering [1]. Market Position - The company has established a strong foothold in the asset management sector and is expanding its client base to include diverse industries such as financial services (excluding asset management), urban management, production management, and telecommunications [2][3]. - The company’s solutions are designed to facilitate seamless deployment in both cloud and on-premise environments, enabling rapid data processing for decision-making [2].

Investment Rating - The report suggests a cautious subscription for the company, indicating a neutral to negative outlook on the investment opportunity [4]. Core Insights - The company operates as a comprehensive prefabricated steel structure construction subcontractor, providing services across various sectors, including project design, procurement, manufacturing, and installation [2]. - The company ranks third in the industrial sector of China's prefabricated steel structure market, with a market share of 3.5% as of 2024, while the top two competitors hold market shares of 35.8% and 6.5% respectively [2]. - The penetration rate of prefabricated construction in the overall construction industry is projected to increase from 20.0% in 2020 to 29.3% in 2024, indicating a growing trend towards prefabricated methods [3]. - The Chinese prefabricated construction market is expected to grow from RMB 448.5 billion in 2020 to RMB 589.3 billion in 2024, with a compound annual growth rate (CAGR) of 7.1% [3]. - Future projections suggest the market will expand further, reaching RMB 707.0 billion by 2029, with a CAGR of 4.6% [3]. - The company's revenue for the six months ending June 30 for 2023, 2024, and 2025 is projected to be RMB 1,453.2 million, RMB 1,523.0 million, and RMB 1,424.1 million respectively, reflecting a significant fluctuation in performance [4]. - The estimated price-to-earnings (PE) ratio for the company based on the subscription price range corresponds to approximately 10.4 to 13.4 times for 2024, which is considered relatively high [4].

Investment Rating - The report recommends subscription for the IPO of the company, indicating a positive investment outlook [1]. Core Insights - The company, established in 2014, operates as a global AI-driven drug discovery and development firm, leveraging its proprietary Pharma.AI platform to generate over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to $2.1 billion [2]. - The company employs a project-based business model, primarily generating revenue through licensing and collaboration agreements, and aims to expand the application of Pharma.AI into various industries, including advanced materials, agriculture, nutrition products, and veterinary medicine [2]. - The AI drug discovery and development (AIDD) market is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6%, positioning the company as a leader in this rapidly growing sector [3]. Financial Performance - The company is currently in the R&D phase, with revenue increasing from $3.01 million in 2022 to $5.12 million in 2023, and further projected to rise to $8.58 million in 2024. For the first half of 2025, revenue was reported at $2.75 million [3]. - Net losses have decreased over the years, with losses of $22.18 million in 2022, $21.16 million in 2023, $1.71 million in 2024, and $1.92 million in the first half of 2025, indicating improving financial health [3]. - The expected market capitalization post-IPO is estimated at HKD 13.4 billion, reflecting the company's potential as a leading player in the domestic AI pharmaceutical sector [3].

Investment Rating - The report suggests a cautious subscription for the IPO of the company, Wan'an Robotics, with a proposed price range of HKD 63 to HKD 81 per share [1][3]. Core Insights - The company is recognized as a leading global provider of home robotic systems, focusing on markets in Japan, Europe, and North America, and aims to build an ecosystem centered around smart home robotic products [1]. - The global home robotics market is projected to grow from RMB 213.3 billion in 2022 to RMB 257.7 billion in 2024, with a compound annual growth rate (CAGR) of 9.9%, and is expected to reach approximately RMB 436.5 billion by 2029, with a CAGR of 11.1% from 2024 to 2029 [2]. - The company's revenue is forecasted to increase significantly, reaching RMB 274.6 million, RMB 457.3 million, and RMB 609.9 million for the years 2022, 2023, and 2024 respectively, reflecting a CAGR of 49.0% [2]. Summary by Sections IPO Details - The total fundraising amount is estimated at HKD 1.5049 billion based on a mid-price of HKD 73 per share, with a total of 22.2223 million shares available for subscription [1]. - The subscription period is from December 18 to December 23, 2025, with an entry fee of HKD 8,181.69 [1]. Market Potential - The home robotics market is currently in a rapid development phase, with an expected increase in product penetration to 29.9% by 2029 [2][3]. - The company has over 3.5 million registered users on its SwitchBotApp, with more than 10.8 million devices connected [1]. Financial Performance - The company has shown improvement in operational efficiency, with net losses decreasing from RMB -86.98 million in 2022 to RMB -3.07 million in 2024 [2].

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 10.04 per share, indicating a potential upside of 22% from the current price of HKD 8.23 [1][4][11]. Core Insights - The innovative drug Seletong Capsule is progressing well in development, having completed Phase III clinical trials and expected to receive production approval in 2026, with market potential targeting vascular dementia, which currently lacks effective treatments [2][6][7]. - The company faced revenue pressure due to industry factors such as centralized procurement, leading to a 16.3% year-on-year decline in revenue for the first three quarters of 2025 [3][8]. - Despite revenue challenges, the company has improved its net profit margin from 30.0% to 37.2% due to reduced sales and distribution costs [3][9]. Financial Summary - Revenue projections for 2025-2027 are estimated at RMB 38.4 billion, RMB 41.1 billion, and RMB 46.0 billion, respectively, with net profits expected to be RMB 9.29 billion, RMB 10.11 billion, and RMB 11.38 billion [4][11]. - The company’s gross margin decreased from 75.3% to 72.2% due to rising raw material costs and pricing pressures from centralized procurement [3][8]. - The company maintains a dividend yield of 6.1%, reflecting its commitment to returning value to shareholders [4][11].

Investment Rating - The report maintains a "Strong Buy" rating for Yuexiu Transportation Infrastructure [6] Core Views - The acquisition of Qinbin Expressway is expected to significantly benefit the company's performance and operational sustainability [2][5] - The project is projected to enhance the company's revenue and extend the average remaining toll collection period of its controlled highways by approximately 0.8 years [5] Summary by Sections Acquisition Details - The company plans to acquire 85% of the Qinbin Expressway for CNY 1.154 billion, covering a total length of 60.7 kilometers with a remaining toll collection period of slightly over 20 years [2] - The expressway has already achieved profitability, with revenues for the years 2023, 2024, and 2025 (up to August) reported at CNY 563 million, CNY 752 million, and CNY 546 million respectively [3] Revenue Potential - The average daily revenue per kilometer for Qinbin Expressway is notably high, at CNY 25,000, CNY 34,000, and CNY 37,000 for the years 2023, 2024, and 2025 respectively [3] - The report anticipates a revenue drop in 2026 to CNY 599 million, which is still above the 2023 level, due to increased traffic on the expressway from the parallel expansion of the Rongwu Expressway [4] Financial Metrics - The internal rate of return (IRR) for the acquisition is estimated at 10.43%, which is favorable compared to the previous acquisition of Pinglin Expressway with an IRR of 9.2% [4] - The total enterprise value (EV) of the project is calculated at CNY 6.225 billion, translating to a unit cost of just over CNY 100 million per kilometer [4] Profit Forecast - The projected net profits for the company for 2025, 2026, and 2027 are CNY 755 million, CNY 769 million, and CNY 822 million respectively, with a significant increase expected from the acquisition [11] - The report suggests that the acquisition will add approximately CNY 1 billion to the company's earnings in 2026 [11]

Investment Rating - The report maintains a rating of "Buy" for CICC, with a target price of HKD 27.20, corresponding to a 1.2x PB for 2025 [6][9]. Core Views - The merger with Dongxing Securities and China Cinda is expected to significantly enhance CICC's overall strength, with synergies anticipated mainly in expanding the customer base and improving asset efficiency [2][9]. - The merger is projected to elevate CICC's ranking in the industry from 8th to 3rd or 4th, with combined net revenue, net profit, total assets, and net assets expected to rank 3rd, 6th, 4th, and 4th respectively in the industry [9]. - The integration is expected to strengthen various business segments, particularly self-operated income, which is anticipated to rise to 3rd place, and improve capital utilization efficiency [9]. Financial Summary - Total revenue is projected to decline from HKD 22,990 million in 2023 to HKD 21,333 million in 2024, before increasing to HKD 25,176 million in 2025, representing an 18.01% growth [5][10]. - Net profit is expected to decrease from HKD 6,156 million in 2023 to HKD 5,694 million in 2024, followed by a significant increase to HKD 8,000 million in 2025, reflecting a 40.50% growth [5][10]. - The PE ratio is forecasted to decrease from 13.56 in 2023 to 10.43 in 2025, indicating a potential undervaluation [5][10]. Market Data - CICC's current stock price is HKD 18.96, with a market capitalization of HKD 91,525 million and a 52-week price range of HKD 11.74 to HKD 23.54 [6][9]. - The average PB ratio for comparable companies is 0.99 for 2024, while CICC's PB is projected at 0.90, suggesting a competitive valuation [12].

港股公司 证 券 研 究 报 告 康耐特光学（02276.HK）重大事项点评 强推（维持） [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 2,061 | 2,347 | 2,835 | 3,380 | | 同比增速(%) | 17.1% | 13.9% | 20.8% | 19.2% | | 归母净利润(百万元) | 428 | 564 | 696 | 869 | | 同比增速(%) | 31.0% | 31.7% | 23.3% | 25.0% | | 每股盈利(元) | 0.89 | 1.18 | 1.45 | 1.81 | | 市盈率(倍) | 48 | 41 | 33 | 27 | | 市净率(倍) | 13.0 | 8.1 | 6.9 | 5.8 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 12 月 17 日收盘价 其他轻工Ⅲ 2025 年 12 月 18 日 春节旺季临近，关注夸克 AI ...

Investment Rating - The report assigns a rating of "Buy" to the company, with a current price of 1.38 HKD and a target value of 1.89 HKD [4]. Core Insights - China Cinda has disclosed significant proposed mergers and acquisitions, which are expected to result in a one-time post-tax gain of approximately 20 billion RMB [1]. - Following the merger, China Cinda will no longer hold any shares in Cinda Securities A-shares and will receive 1.3 billion shares in China International Capital Corporation (CICC), representing about 16.71% of CICC's equity [1]. - The proposed merger is anticipated to generate substantial one-time earnings due to the shift from cost method to fair value accounting for the merger [1]. Financial Forecast - Revenue is projected to decline from 76.17 billion RMB in 2023 to 73.04 billion RMB in 2024, with a slight recovery expected in subsequent years [2]. - Net profit attributable to shareholders is forecasted to drop significantly from 5.82 billion RMB in 2023 to 3.04 billion RMB in 2024, before rebounding to 3.67 billion RMB in 2025 [2]. - Earnings per share (EPS) is expected to decrease from 0.11 RMB in 2023 to 0.04 RMB in 2024, with a gradual increase to 0.16 RMB by 2027 [2]. Business Operations - The company has focused on acquiring non-performing assets, with the scale of operational acquisitions increasing year-on-year despite a decline in disposal scale due to economic conditions [8]. - The internal rate of return for operational acquisitions in the first half of 2025 was 8.7%, slightly down from 8.9% in the previous year [8]. - Revenue from acquisition and restructuring business fell by 65.5% year-on-year in the first half of 2025, indicating a structured exit from these assets [8]. Valuation Metrics - The report provides a price-to-earnings (P/E) ratio forecast of 6.32 for 2023, increasing to 24.03 by 2025, before decreasing to 7.87 by 2027 [2]. - The price-to-book (P/B) ratio is projected to rise from 0.17 in 2023 to 0.29 in 2025, then stabilize around 0.25 by 2027 [2].